Business, energy, technology, markets and global industry news from Business News Today

FDA

PharmaDeviceNews FDA
Representative image: An ENT specialist explains a sinus procedure as Airiver Medical’s ESSpand Sinus Drug Coated Balloon trial highlights new drug-device approaches for chronic rhinosinusitis care.
Medical Devices & Diagnostics

Could Airiver Medical’s ESSpand balloon reduce repeat procedures in chronic rhinosinusitis?

Find out how Airiver Medical’s ESSpand pivotal trial could reshape chronic rhinosinusitis care and sinus surgery outcomes.

Read More
Representative image: A dermatologist examines an eczema flare, reflecting how EBGLYSS and other atopic dermatitis biologics are shifting the treatment conversation toward fewer injections, longer disease control, and lower patient burden.
Features & Analysis

How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy

Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.

Read More
Representative image: A clinician uses a handheld skin assessment device, reflecting DermaSensor’s CE Mark and the growing role of AI-assisted skin cancer triage in European primary care.
Pharma & Biotech

Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?

Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.

Read More
Representative image: A paediatric audiology assessment highlights the clinical focus behind Sensorion’s SENS-601 gene therapy program for GJB2-related hearing loss.
Pharma & Biotech

Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets

Find out how Sensorion’s SENS-601 regulatory push could reshape GJB2 hearing loss gene therapy and clinical strategy.

Read More
Representative image of CNS drug development and neuroscience research, highlighting Enveric Biosciences’ EB-003 push toward clinical-stage neuroplastogen testing.
Pharma & Biotech

Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development

Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.

Read More
Representative image: Non-invasive elbow therapy highlights MR5 ACTIV PRO’s FDA-cleared role in temporary tennis elbow pain relief.
Medical Devices & Diagnostics

Why Multi Radiance Medical’s MR5 ACTIV PRO clearance matters for tendon pain treatment

Read how Multi Radiance Medical’s MR5 ACTIV PRO clearance could reshape non-invasive tennis elbow pain treatment and what risks remain.

Read More
Representative image: A PET/CT imaging suite illustrates how Pentixapharm’s [68Ga]Ga-PentixaFor Phase 3 PANDA study could reshape primary aldosteronism diagnostics and cardiovascular precision medicine.
Medical Devices & Diagnostics

Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset

See why Pentixapharm’s Phase 3 CXCR4 PET/CT push could challenge a stubborn diagnostic bottleneck in primary aldosteronism.

Read More
Representative image: A clinician reviews spinal imaging for chronic low back pain as Vertanical’s Exilby approval highlights the growing push for regulated non-opioid pain treatments in Europe.
Pharma & Biotech

Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight

Exilby’s German approval gives chronic pain medicine a rare non-opioid test case. Can Vertanical convert data into adoption?

Read More
Representative image of an intensive care unit ventilator setup, highlighting how diaphragm stimulation devices such as Lungpacer Medical’s AeroPace System could help hospitals support faster ventilator weaning in critically ill patients.
Medical Devices & Diagnostics

Can Lungpacer Medical’s AeroPace System change the economics of ventilator recovery?

AeroPace moves into East Coast ICU care as hospitals test whether diaphragm stimulation can shorten ventilator recovery. Read the analysis.

Read More
Representative image: A pediatric neurology research setting highlights the clinical focus on tralesinidase alfa, enzyme replacement therapy, and long-term treatment advances for Sanfilippo syndrome type B.
Pharma & Biotech

Could Spruce Biosciences finally change the Sanfilippo syndrome type B treatment landscape?

Spruce Biosciences’ MPS IIIB data raise a pivotal question: can tralesinidase alfa turn biomarker gains into disease-changing therapy?

Read More